Tatyana Gustafson
Psychiatric/Mental Health · Austin, TXNPI 1225365943
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 398 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 19.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,502, 5.3 times the $469 reported in 2021. Among psychiatric/mental health clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 398 payments — averaging $21.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Otsuka America Pharmaceutical, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$891
- Alkermes, Inc.$890
- Takeda Pharmaceuticals U.S.A., Inc.$508
- Lundbeck LLC$496
- plus $3K from 19 others
What the payments were for
- Food & beverage$8,367100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 98 | $1,658 |
| Otsuka America Pharmaceutical, Inc. | 48 | $1,115 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 39 | $891 |
| Alkermes, Inc. | 41 | $890 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $508 |
| Lundbeck LLC | 23 | $496 |
| Bausch Health US, LLC | 19 | $402 |
| Johnson & Johnson | 19 | $375 |
| Axsome Therapeutics, Inc. | 13 | $333 |
| Neurocrine Biosciences, Inc. | 10 | $327 |
| Vanda Pharmaceuticals Inc. | 17 | $318 |
| Corium, LLC | 13 | $248 |
| Teva Pharmaceuticals USA, Inc. | 8 | $180 |
| Biogen | 1 | $121 |
| Ironshore Pharmaceuticals Inc. | 5 | $94 |
| Idorsia Pharmaceuticals US Inc | 5 | $87 |
| Sunovion Pharmaceuticals Inc. | 3 | $66 |
| Acadia Pharmaceuticals Inc | 2 | $54 |
| Collegium Pharmaceutical, Inc. | 2 | $42 |
| Noven Therapeutics, LLC | 2 | $42 |
| Alfasigma USA, Inc. | 2 | $37 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $32 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Noven Pharmaceuticals, Inc. | 1 | $17 |
| Vertical Pharmaceuticals, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ABILIFY MAINTENA$125
- ABILIFY ASIMTUFII$125
- VRAYLAR$125
- REXULTI$124
- CAPLYTA$121
- INGREZZA$118
How this compares
$8,367 in reported general payments places this provider in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bupropion XlBupropion Hcl | 20 | $457 |
| Trazodone Hcl | 18 | $334 |
| Quetiapine Fumarate | 16 | $288 |
| Gabapentin | 11 | $193 |
| Clonazepam | 19 | $121 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Austin
- Jaime Nelson DensonAustin$88K
- Camille WatsonAustin$34K
- Suzanne GranthamAustin$31K
- Lin CaiAustin$16K
- Tracy HicksLongview$684K
- Natalie TellezHouston$602K
- Karah BrashierRichardson$567K
- Grant DavisRichardson$360K
- Victor IlogEl Paso$167K
- Lisa ShamblinGrapevine$163K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.